Category: PharmaceuticalsSyndicate content

Pyott out after Actavis closes $70B Allergan buyout

March 18, 2015 by Mark Hollmer

Former Allergan CEO David Pyott will not get a seat on the board at Actavis after all, now that their $70 billion merger is done.

Pyott out after Actavis closes $70B Allergan buyout

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bayer aims to boost drugs sales, margins over next 3 years

March 11, 2015 by MassDevice

Bayer says it plans to grow its main healthcare division by 6% annually over the next 3 years.

Bayer aims to boost drugs sales, margins over next 3 years

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic gets in on Flex Pharma IPO

March 5, 2015 by Mark Hollmer

Medtronic invests in anti-leg-cramp drug maker Flex Pharma's initial public offering.

Medtronic gets in on Flex Pharma IPO

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Pfizer offers $15 billion for Hospira

February 5, 2015 by MassDevice

Pfizer looks to bolster its generics footprint with a $15 billion bid for Hospira.

Pfizer offers $15 billion for Hospira

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

November 17, 2014 by Brad Perriello

Allergan agrees to a $66 billion takeover bid from Actavis, thwarting a hostile takeover bid by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management.

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

Source: Allergan near $66B buyout to escape Valeant, Ackman

November 17, 2014 by MassDevice

Allergan is close to sealing a deal worth nearly $66 billion with Actavis and giving the slip to a hostile takeover bid from Valeant Pharmaceuticals and William Ackman's Pershing Square hedge fund.

Source: Allergan near $66B buyout to escape Valeant, Ackman

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Capricor buys Medtronic peptide patent rights

November 12, 2014 by Val Kennedy

Capricor Therapeutics acquires Medtronic's patent rights for the formulation and delivery of natriuretic peptides to treat heart failure.

Capricor buys Medtronic peptide patent rights

Capricor Therapeutics said it acquired Medtronic's (NYSE:MDT) patent rights for the formulation and delivery of natriuretic peptides.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.